Acasti Pharma (ACST) said Friday it will change its corporate name to Grace Therapeutics and begin trading on Nasdaq under its new ticker, "GRCE" on Oct. 28.
The name change reflects the company's origin and brand equity from Grace Therapeutics, which developed GTx-104 before merging with Acasti in 2021.
Acasti said it expects to release trial data for GTx-104, an injectable formulation targeting aneurysmal subarachnoid hemorrhage, in early 2025 aiming to submit a new drug application to the US Food and Drug Administration in H1 2025.
The company also said it has re-domiciled to the US as a Delaware corporation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。